--- title: "Psych News Alert: Buprenorphine/Naloxone May Be More Effective Than SSRIs for Patients With PTSD" description: Buprenorphine/naloxone may help decrease symptoms of posttraumatic stress disorder (PTSD) more than selective serotonin reuptake inhibito... image: https://alert.psychnews.org/hubfs/Imported_Blog_Media/Therapist_149934155-Jun-24-2025-07-47-34-9403-PM.jpg --- 1/25/19 12:00 AM # Buprenorphine/Naloxone May Be More Effective Than SSRIs for Patients With PTSD ![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [ Psychiatric News Alert ](https://alert.psychnews.org/author/psychiatric-news-alert) Share: [facebook-f icon ](http://www.facebook.com/share.php?u=https://alert.psychnews.org/2019/01/buprenorphinenaloxone-may-be-more.html) [linkedin-in icon ](http://www.linkedin.com/shareArticle?mini=true&url=https://alert.psychnews.org/2019/01/buprenorphinenaloxone-may-be-more.html) [Twitter icon ](https://twitter.com/intent/tweet?url=https://alert.psychnews.org/2019/01/buprenorphinenaloxone-may-be-more.html) [pinterest-p icon ](http://pinterest.com/pin/create/link/?url=https://alert.psychnews.org/2019/01/buprenorphinenaloxone-may-be-more.html) [envelope icon ](mailto:?body=https://alert.psychnews.org/2019/01/buprenorphinenaloxone-may-be-more.html) | ![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/Therapist_149934155-Jun-24-2025-07-47-34-2156-PM.jpg?width=200&height=133&name=Therapist_149934155-Jun-24-2025-07-47-34-2156-PM.jpg) | | | --- | --- | Buprenorphine/naloxone may help decrease symptoms of posttraumatic stress disorder (PTSD) more than selective serotonin reuptake inhibitors (SSRIs) or opioids alone, according to a [study](https://onlinelibrary.wiley.com/doi/10.1111/ajad.12860) published in the *American Journal on Addictions*. Elizabeth P. Lake, Pharm.D., B.C.P.P., of the Central Arkansas Veterans Healthcare System in North Little Rock, Ark., and colleagues conducted a retrospective chart review of 165 patients with PTSD who were treated at the Michael E. DeBakey Veterans Affairs Medical Center between June 1, 2010, and June 30, 2016. The researchers divided the patients into three groups: those taking buprenorphine/naloxone, those taking an SSRI, and those taking other opioid medications. There were 55 patients in each group. The researchers compared the patients’ initial scores on the PTSD Checklist for Clinicians, VA Primary Care PTSD Screen, or both, with the patients’ last scores for the study period. They found that patients in the buprenorphine/naloxone group had significantly decreased symptoms compared with those in the SSRI group. There were no significant differences in symptoms between the buprenorphine/naloxone group and the opioid group or between the opioid group and the SSRI group. When looking at the patients’ initial and final PTSD scores, the researchers found that those in the buprenorphine/naloxone group experienced a 24% decrease in symptoms since their first evaluation, compared with a 16.2% decrease for those in the opioid group. However, PTSD symptom scores increased 1.16% in those taking SSRIs. “Buprenorphine/naloxone showed both a statistically significant and clinically significant change in PTSD scores as compared to SSRIs, which are the current mainstay of pharmacotherapeutic treatment for PTSD,” Lake and colleagues wrote. The researchers cited several limitations to the study, notably that confounding factors such as comorbid conditions were not included in the statistical analysis because of constraints in the modeling software. The researchers also did not assess whether patients were undergoing psychotherapy for PTSD or a substance use disorder or had a concurrent diagnosis for opioid use disorder. “Prospective randomized trials utilizing current PTSD symptom scales are warranted to evaluate if buprenorphine/naloxone may represent a potential pharmacotherapeutic option for the treatment of PTSD,” they concluded. For related information, see the *Psychiatric News* article “[Propranolol Combined With Reactivation Therapy May Reduce PTSD Symptoms](https://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2018.pp2a2).” (Image: Pressmaster/Shutterstock) --- ## Have You Voted in APA’s 2019 Election Yet? If not, take a moment to do so now: Voting closes on Thursday, January 31. Learn about this year’s slate of candidates, their priorities, and backgrounds at the [APA elections page](https://www.psychiatry.org/psychiatrists/awards-leadership-opportunities/leadership-opportunities/elections) and watch video interviews of the candidates for president-elect and secretary. Click [here](https://www.psychiatry.org/psychiatrists/awards-leadership-opportunities/leadership-opportunities/elections) to vote now and be part of the process. [![](https://alert.psychnews.org/hubfs/Imported_Blog_Media/Twitter_Bird-Jun-24-2025-07-51-16-8970-PM.png)](https://alert.psychnews.org/hubfs/Imported_Blog_Media/Twitter_Bird-Jun-24-2025-07-51-16-8970-PM.png) **[Follow *Psychiatric News* on Twitter!](https://twitter.com/PsychiatricNews)** [SSRI](https://alert.psychnews.org/tag/ssri), [PTSD](https://alert.psychnews.org/tag/ptsd), [selective serotonin reuptake inhibitor](https://alert.psychnews.org/tag/selective-serotonin-reuptake-inhibitor), [posttraumatic stress disorder](https://alert.psychnews.org/tag/posttraumatic-stress-disorder), [naloxone](https://alert.psychnews.org/tag/naloxone), [buprenorphine](https://alert.psychnews.org/tag/buprenorphine) ## Related posts [![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/group_therapy_iStock-1487326347-Jun-24-2025-05-26-25-8148-PM.jpg?height=200&name=group_therapy_iStock-1487326347-Jun-24-2025-05-26-25-8148-PM.jpg) ](https://alert.psychnews.org/2024/12/sertraline-plus-brexpiprazole-may-be.html) [SSRI](https://alert.psychnews.org/tag/ssri), [PTSD](https://alert.psychnews.org/tag/ptsd), [posttraumatic stress disorder](https://alert.psychnews.org/tag/posttraumatic-stress-disorder), [sertraline](https://alert.psychnews.org/tag/sertraline), [clinical trial](https://alert.psychnews.org/tag/clinical-trial), [brexpiprazole](https://alert.psychnews.org/tag/brexpiprazole), [arousal](https://alert.psychnews.org/tag/arousal) ## [Sertraline Plus Brexpiprazole May Be Effective Combo for PTSD](https://alert.psychnews.org/2024/12/sertraline-plus-brexpiprazole-may-be.html) ![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 12/20/24 12:00 AM [ Read more ](https://alert.psychnews.org/2024/12/sertraline-plus-brexpiprazole-may-be.html) [![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/Soldier_76418410-Jun-24-2025-03-34-38-9050-PM.jpg?height=200&name=Soldier_76418410-Jun-24-2025-03-34-38-9050-PM.jpg) ](https://alert.psychnews.org/2011/12/va-shuffles-schedules-to-see-more-first.html) [PTSD](https://alert.psychnews.org/tag/ptsd), [VA](https://alert.psychnews.org/tag/va), [veterans health care](https://alert.psychnews.org/tag/veterans-health-care) ## [VA Shuffles Schedules to See More First-Time Patients](https://alert.psychnews.org/2011/12/va-shuffles-schedules-to-see-more-first.html) ![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 12/1/11 12:00 AM [ Read more ](https://alert.psychnews.org/2011/12/va-shuffles-schedules-to-see-more-first.html) [![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/shutterstock_101982913-Jun-24-2025-06-12-16-5762-PM.jpg?height=200&name=shutterstock_101982913-Jun-24-2025-06-12-16-5762-PM.jpg) ](https://alert.psychnews.org/2012/07/trauma-ptsd-common-in-patients-with.html) [PTSD](https://alert.psychnews.org/tag/ptsd), [serious mental illness](https://alert.psychnews.org/tag/serious-mental-illness) ## [Trauma, PTSD Common in Patients With Severe Mental Disorders](https://alert.psychnews.org/2012/07/trauma-ptsd-common-in-patients-with.html) ![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 7/27/12 12:00 AM Experiencing traumatic experiences and developing posttraumatic stress disorder (PTSD) are more... [ Read more ](https://alert.psychnews.org/2012/07/trauma-ptsd-common-in-patients-with.html) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Psychiatric News Alert", "url" : "https://alert.psychnews.org/author/psychiatric-news-alert" }, "dateModified" : "2025-06-24T19:52:06.885Z", "datePublished" : "2019-01-25T05:00:00.000Z", "headline" : "Psych News Alert: Buprenorphine/Naloxone May Be More Effective Than SSRIs for Patients With PTSD", "image" : [ "https://alert.psychnews.org/hubfs/Imported_Blog_Media/Therapist_149934155-Jun-24-2025-07-47-34-9403-PM.jpg" ], "mainEntityOfPage" : { "@id" : "https://alert.psychnews.org/2019/01/buprenorphinenaloxone-may-be-more.html", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://alert.psychnews.org/hubfs/PN-Blue-Box.jpg" } } } ```